Defunct Company
Total Trials
4
As Lead Sponsor
As Collaborator
0
Total Enrollment
86
NCT04110496
Safety and Tolerability of RTX-134 in Adults With Phenylketonuria
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 29, 2020
Completion: Dec 1, 2022
NCT04372706
RTX-240 Monotherapy and in Combination With Pembrolizumab
Phase: Phase 1/2
Start: May 6, 2020
Completion: Nov 30, 2022
NCT04672980
RTX-321 Monotherapy in Patients With HPV 16+ Tumors
Start: Apr 8, 2021
NCT05219578
RTX-224 Monotherapy in Patients With Solid Tumors
Start: Jan 12, 2022